Anti-Tau Monoclonal Antibody (Clone:IHC696)
|Amount :||0.5 ml|
|Isotype :||Mouse IgG1|
|Purification :||Protein A/G Chromatography|
|Content :||Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide|
|Storage condition :||Store at 2°C - 8°C. Do not freeze.|
Tau proteins are abundant in neurons of the central nervous system, and function in microtubule stability and organization. Defects in Tau functioning and aggregation of these proteins have been clinically linked to a number of neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Pick’s disease (PiD), progressive supranuclear palsy (PSP), cortical basal degeneration (CBD), and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).
Recommended dilutions: Immunohistochemical analysis: 1:100 - 1:200. However, this need to be optimized based on the research applications.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|Subcellular location:||Cytoplasm, Cell membrane, Cytoplasm, Cell projection, Cytoplasm, Cell projection|
|Post transnational modification:||Glycation of PHF-tau, but not normal brain TAU/MAPT. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.|
|Tissue Specificity:||Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.|
|BioGrid:||110308. 118 interactions.|